Fighting cancer: Rocky path for immunotherapy

High hopes that new immunotherapy drugs would prove to have benefits over toxic chemotherapy were dashed by large-scale trials, says David Crow. Pharmaceutical groups are now working on combinations of the immunotherapies and using them with chemo, but some pharma groups have suffered big losses and Wall Street has become sceptical

Hosted on Acast. See acast.com/privacy for more information.